Xilio Therapeutics (United States)

Photochemical Kinetics of Corneal Cross-Linking with Riboflavin

Pavel Kamaev, Marc D. Friedman, Evan Sherr et al. · Investigative Ophthalmology & Visual Science · 2012 · 309 citations

RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations

Vivek Subbiah, Vaibhav Sahai, Dejan Maglic et al. · Cancer Discovery · 2023 · 103 citations · Full text

A potent and selective PARP14 inhibitor decreases protumor macrophage gene expression and elicits inflammatory responses in tumor explants

Laurie B. Schenkel, Jennifer R. Molina, Kerren K. Swinger et al. · Cell chemical biology · 2021 · 71 citations · Full text

Inflammation, Selective Parp14 Inhibitor, Inflammatory Responses +10

Overcoming adaptive resistance to anti-VEGF therapy by targeting CD5L

Christopher J. Lafargue, Paola Amero, Kyunghee Noh et al. · Nature Communications · 2023 · 34 citations · Full text

Pharmacokinetics of novel Fc-engineered monoclonal and multispecific antibodies in cynomolgus monkeys and humanized FcRn transgenic mouse models

Delphine Valente, Christine Mauriac, Thorsten Schmidt et al. · mAbs · 2020 · 28 citations · Full text